15-(Ortho-123i-phenyl)-pentadecanoic acid, a new myocardial imaging agent for clinical use

M. A. Antar, G. Spohr, H. H. Herzog, K. P. Kaiser, G. Notohamiprodjo, E. Vester, B. Schwartzkopf, B. Lösse, H. J. Machulla, W. W. Shreeve, L. E. Feinendegen

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The result of previous experiments in rodents indicated different kinetics for the para- and ortho-isomers of 15-(iodophenyl)-pentadecanoic add (p-IPPA, o-IPPA), with o-IPPA showing an enhanced rate of washout. To test the relevance of this phenomenon for clinical diagnosis, 15 fasting male patients with confirmed coronary heart disease (l-VD/7,2-VD/4,3-VD/4) were investigated under exercise. Serial images were recorded at a rate of 3 frames min"1 for 70 to 90 min, corrected for tracer in blood and compared with thallium-201 images obtained from these patients within less than 2 weeks. Time-activity curves were also taken from the peripheral blood Ortho-IPPA was well taken up by healthy myocardium and, contrary to rodents, retained with elimination half times longer than 200 min. A decreased myocardial uptake was seen which was very similar to the pattern obtained with thallium. Ortho-IPPA was eliminated from the blood to < 10% at 4 min. Almost all radioactivity was in the organic phase (> 95% at 5 min) and chromatography showed only one major peak (o-IPPA) indicative of minimal organic catabolism.

Original languageEnglish
Pages (from-to)683-696
Number of pages14
JournalNuclear Medicine Communications
Volume7
Issue number9
DOIs
StatePublished - Sep 1986
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of '15-(Ortho-123i-phenyl)-pentadecanoic acid, a new myocardial imaging agent for clinical use'. Together they form a unique fingerprint.

Cite this